Migraine-Pipeline Review, H1 2015

Migraine-Pipeline Review, H1 2015

  • Products Id :- GMDHC6692IDB
  • |
  • Pages: 199
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Migraine-Pipeline Review, H1 2015


Global Markets Direct's, 'Migraine-Pipeline Review, H1 2015', provides an overview of the Migraine's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Migraine, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Migraine and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


The report provides a snapshot of the global therapeutic landscape of Migraine

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Migraine and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Migraine products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Migraine pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Migraine

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Migraine pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Read More

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications


Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 8

Introduction 9

Global Markets Direct Report Coverage 9

Migraine Overview 10

Therapeutics Development 11

Pipeline Products for Migraine-Overview 11

Pipeline Products for Migraine-Comparative Analysis 12

Migraine-Therapeutics under Development by Companies 13

Migraine-Therapeutics under Investigation by Universities/Institutes 18

Migraine-Pipeline Products Glance 19

Late Stage Products 19

Clinical Stage Products 20

Early Stage Products 21

Unknown Stage Products 22

Migraine-Products under Development by Companies 23

Migraine-Products under Investigation by Universities/Institutes 27

Migraine-Companies Involved in Therapeutics Development 28

Ache Laboratorios Farmaceuticos S/A 28

Acorda Therapeutics, Inc. 29

Alder Biopharmaceuticals Inc. 30

Allergan, Inc. 31

Amgen Inc. 32

Astellas Pharma Inc. 33

BioDelivery Sciences International, Inc. 34

Biofrontera AG 35

Bristol-Myers Squibb Company 36

Charleston Laboratories, Inc. 37

CoLucid Pharmaceuticals, Inc. 38

D-Pharm Ltd. 39

Dr. Reddy's Laboratories Limited 40

Eli Lilly and Company 41

Heptares Therapeutics Limited 42

iCeutica, Inc. 43

Mallinckrodt Plc 44

Medestea Research & Production S.p.A. 45

Merck & Co., Inc. 46

Monosol Rx, LLC 47

NAL Pharmaceuticals Ltd. 48

Nektar Therapeutics 49

NeurAxon, Inc. 50

Northern Light Pharmaceuticals AB 51

Noxxon Pharma AG 52

Otsuka Holdings Co., Ltd. 53

Paladin Labs Inc. 54

Pantarhei Bioscience BV 55

Pivot Pharmaceuticals Inc 56

Pozen, Inc. 57

RedHill Biopharma Ltd. 58

Revance Therapeutics, Inc. 59

Shin Nippon Biomedical Laboratories, Ltd. 60

Suda Ltd 61

Teva Pharmaceutical Industries Limited 62

TheraJect, Inc. 63

Trevena, Inc. 64

Trigemina, Inc. 65

Vertex Pharmaceuticals Incorporated 66

Migraine-Therapeutics Assessment 67

Assessment by Monotherapy Products 67

Assessment by Combination Products 68

Assessment by Target 69

Assessment by Mechanism of Action 72

Assessment by Route of Administration 75

Assessment by Molecule Type 77

Drug Profiles 79

(dextromethorphan hydrobromide + quinidine sulfate)-Drug Profile 79

(naproxen sodium + naratriptan hydrochloride)-Drug Profile 81

(sumatriptan succinate + naproxen sodium)-Drug Profile 82

AA-71-Drug Profile 84

ALD-403-Drug Profile 85

AMG-334-Drug Profile 87

BEMA Triptan-Drug Profile 88

BF-1-Drug Profile 89

C-012-Drug Profile 90

CLH-1T-Drug Profile 91

corticotropin-Drug Profile 92

CVT-427-Drug Profile 94

Deina-Drug Profile 95

DFN-02-Drug Profile 96

DFN-11-Drug Profile 97

DFP-02-Drug Profile 98

dihydroergotamine mesylate-Drug Profile 99

dihydroergotamine mesylate-Drug Profile 102

DORA-12-Drug Profile 103

DP-VPA-Drug Profile 104

esterol-Drug Profile 106

histamine dihydrochloride-Drug Profile 108

ICE-1209-Drug Profile 109

ICE-1210-Drug Profile 110

ICE-1211-Drug Profile 111

IPX-232-Drug Profile 112

ketoprofen-Drug Profile 113

lasmiditan succinate-Drug Profile 115

LY-2951742-Drug Profile 117

NKTR-192-Drug Profile 119

NOXL-41-Drug Profile 120

NXN-188-Drug Profile 121

NXN-462-Drug Profile 122

oxytocin-Drug Profile 123

P-003-Drug Profile 124

picotamide-Drug Profile 125

Protein to Activate Insulin Like Growth Factor 1 Receptor for Migraine-Drug Profile 126

Rimegepant sulfate-Drug Profile 127

rizatriptan benzoate-Drug Profile 129

rizatriptan benzoate-Drug Profile 131

rizatriptan benzoate-Drug Profile 132

RT-001-Drug Profile 133

Small Molecule to Antagonize CGRP for Migraine-Drug Profile 135

Small Molecule to Antagonize CGRP Receptor for Migraine-Drug Profile 136

Small Molecule to Inhibit GABA Transaminase for Migraine and Status Epilepticus-Drug Profile 137

Small Molecule to Inhibit nNOS/NET for Migraine and Neuropathic Pain-Drug Profile 138

Small Molecule to Inhibit Prostaglandin E2 for Pain-Drug Profile 139

Small Molecules to Inhibit 5-HT2B and 5-HT7 Receptors for IBS and Migraine-Drug Profile 140

Small Molecules to Inhibit CGRP Receptor for Migraine-Drug Profile 141

Small Molecules to Inhibit Nitric Oxide Synthase for CNS Disorders-Drug Profile 142

SST-8055-Drug Profile 143

sumatriptan succinate-Drug Profile 144

sumatriptan succinate-Drug Profile 145

sumatriptan succinate-Drug Profile 147

sumatriptan succinate-Drug Profile 149

TEV-48125-Drug Profile 150

Tribarcina-Drug Profile 152

TRV-250-Drug Profile 153

zolmitriptan-Drug Profile 154

zolmitriptan-Drug Profile 155

Migraine-Recent Pipeline Updates 156

Migraine-Dormant Projects 178

Migraine-Discontinued Products 184

Migraine-Product Development Milestones 186

Featured News & Press Releases 186

Appendix 194

Methodology 194

Coverage 194

Secondary Research 194

Primary Research 194

Expert Panel Validation 194

Contact Us 194

Disclaimer 195

List of Tables

Number of Products under Development for Migraine, H1 2015 15

Number of Products under Development for Migraine-Comparative Analysis, H1 2015 16

Number of Products under Development by Companies, H1 2015 18

Number of Products under Development by Companies, H1 2015 (Contd..1) 19

Number of Products under Development by Companies, H1 2015 (Contd..2) 20

Number of Products under Development by Companies, H1 2015 (Contd..3) 21

Number of Products under Investigation by Universities/Institutes, H1 2015 22

Comparative Analysis by Late Stage Development, H1 2015 23

Comparative Analysis by Clinical Stage Development, H1 2015 24

Comparative Analysis by Early Stage Development, H1 2015 25

Comparative Analysis by Unknown Stage Development, H1 2015 26

Products under Development by Companies, H1 2015 27

Products under Development by Companies, H1 2015 (Contd..1) 28

Products under Development by Companies, H1 2015 (Contd..2) 29

Products under Development by Companies, H1 2015 (Contd..3) 30

Products under Investigation by Universities/Institutes, H1 2015 31

Migraine-Pipeline by Ache Laboratorios Farmaceuticos S/A, H1 2015 32

Migraine-Pipeline by Acorda Therapeutics, Inc., H1 2015 33

Migraine-Pipeline by Alder Biopharmaceuticals Inc., H1 2015 34

Migraine-Pipeline by Allergan, Inc., H1 2015 35

Migraine-Pipeline by Amgen Inc., H1 2015 36

Migraine-Pipeline by Astellas Pharma Inc., H1 2015 37

Migraine-Pipeline by BioDelivery Sciences International, Inc., H1 2015 38

Migraine-Pipeline by Biofrontera AG, H1 2015 39

Migraine-Pipeline by Bristol-Myers Squibb Company, H1 2015 40

Migraine-Pipeline by Charleston Laboratories, Inc., H1 2015 41

Migraine-Pipeline by CoLucid Pharmaceuticals, Inc., H1 2015 42

Migraine-Pipeline by D-Pharm Ltd., H1 2015 43

Migraine-Pipeline by Dr. Reddy's Laboratories Limited, H1 2015 44

Migraine-Pipeline by Eli Lilly and Company, H1 2015 45

Migraine-Pipeline by Heptares Therapeutics Limited, H1 2015 46

Migraine-Pipeline by iCeutica, Inc., H1 2015 47

Migraine-Pipeline by Mallinckrodt Plc, H1 2015 48

Migraine-Pipeline by Medestea Research & Production S.p.A., H1 2015 49

Migraine-Pipeline by Merck & Co., Inc., H1 2015 50

Migraine-Pipeline by Monosol Rx, LLC, H1 2015 51

Migraine-Pipeline by NAL Pharmaceuticals Ltd., H1 2015 52

Migraine-Pipeline by Nektar Therapeutics, H1 2015 53

Migraine-Pipeline by NeurAxon, Inc., H1 2015 54

Migraine-Pipeline by Northern Light Pharmaceuticals AB, H1 2015 55

Migraine-Pipeline by Noxxon Pharma AG, H1 2015 56

Migraine-Pipeline by Otsuka Holdings Co., Ltd., H1 2015 57

Migraine-Pipeline by Paladin Labs Inc., H1 2015 58

Migraine-Pipeline by Pantarhei Bioscience BV, H1 2015 59

Migraine-Pipeline by Pivot Pharmaceuticals Inc, H1 2015 60

Migraine-Pipeline by Pozen, Inc., H1 2015 61

Migraine-Pipeline by RedHill Biopharma Ltd., H1 2015 62

Migraine-Pipeline by Revance Therapeutics, Inc., H1 2015 63

Migraine-Pipeline by Shin Nippon Biomedical Laboratories, Ltd., H1 2015 64

Migraine-Pipeline by Suda Ltd, H1 2015 65

Migraine-Pipeline by Teva Pharmaceutical Industries Limited, H1 2015 66

Migraine-Pipeline by TheraJect, Inc., H1 2015 67

Migraine-Pipeline by Trevena, Inc., H1 2015 68

Migraine-Pipeline by Trigemina, Inc., H1 2015 69

Migraine-Pipeline by Vertex Pharmaceuticals Incorporated, H1 2015 70

Assessment by Monotherapy Products, H1 2015 71

Assessment by Combination Products, H1 2015 72

Number of Products by Stage and Target, H1 2015 74

Number of Products by Stage and Mechanism of Action, H1 2015 77

Number of Products by Stage and Route of Administration, H1 2015 80

Number of Products by Stage and Molecule Type, H1 2015 82

Migraine Therapeutics-Recent Pipeline Updates, H1 2015 160

Migraine-Dormant Projects, H1 2015 182

Migraine-Dormant Projects (Contd..1), H1 2015 183

Migraine-Dormant Projects (Contd..2), H1 2015 184

Migraine-Dormant Projects (Contd..3), H1 2015 185

Migraine-Dormant Projects (Contd..4), H1 2015 186

Migraine-Dormant Projects (Contd..5), H1 2015 187

Migraine-Discontinued Products, H1 2015 188

Migraine-Discontinued Products (Contd..1), H1 2015 189

List of Figures

Number of Products under Development for Migraine, H1 2015 15

Number of Products under Development for Migraine-Comparative Analysis, H1 2015 16

Number of Products under Development by Companies, H1 2015 17

Number of Products under Investigation by Universities/Institutes, H1 2015 22

Comparative Analysis by Late Stage Development, H1 2015 23

Comparative Analysis by Clinical Stage Development, H1 2015 24

Comparative Analysis by Early Stage Products, H1 2015 25

Assessment by Monotherapy Products, H1 2015 71

Assessment by Combination Products, H1 2015 72

Number of Products by Top 10 Targets, H1 2015 73

Number of Products by Stage and Top 10 Targets, H1 2015 73

Number of Products by Top 10 Mechanism of Actions, H1 2015 76

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 76

Number of Products by Top 10 Routes of Administration, H1 2015 79

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 79

Number of Products by Top 10 Molecule Types, H1 2015 81

Number of Products by Stage and Top 10 Molecule Types, H1 2015 81

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com

Ache Laboratorios Farmaceuticos S/A

Acorda Therapeutics, Inc.

Alder Biopharmaceuticals Inc.

Allergan, Inc.

Amgen Inc.

Astellas Pharma Inc.

BioDelivery Sciences International, Inc.

Biofrontera AG

Bristol-Myers Squibb Company

Charleston Laboratories, Inc.

CoLucid Pharmaceuticals, Inc.

D-Pharm Ltd.

Dr. Reddy's Laboratories Limited

Eli Lilly and Company

Heptares Therapeutics Limited

iCeutica, Inc.

Mallinckrodt Plc

Medestea Research & Production S.p.A.

Merck & Co., Inc.

Monosol Rx, LLC

NAL Pharmaceuticals Ltd.

Nektar Therapeutics

NeurAxon, Inc.

Northern Light Pharmaceuticals AB

Noxxon Pharma AG

Otsuka Holdings Co., Ltd.

Paladin Labs Inc.

Pantarhei Bioscience BV

Pivot Pharmaceuticals Inc

Pozen, Inc.

RedHill Biopharma Ltd.

Revance Therapeutics, Inc.

Shin Nippon Biomedical Laboratories, Ltd.

Suda Ltd

Teva Pharmaceutical Industries Limited

TheraJect, Inc.

Trevena, Inc.

Trigemina, Inc.

Vertex Pharmaceuticals Incorporated

Migraine Therapeutic Products under Development, Key Players in Migraine Therapeutics, Migraine Pipeline Overview, Migraine Pipeline, Migraine Pipeline Assessment

select a license

Single User License
USD 2000 INR 132300
Site License
USD 4000 INR 264600
Corporate User License
USD 6000 INR 396900



The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...

Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

sales [@] kenresearch.com